Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.
about
CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapyAKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicinA critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistanceABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra?Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML).Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas.High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patientsMDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model.Targeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in Acute Myeloid Leukaemia.PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanismCD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.Molecular evidence and functional expression of a novel drug efflux pump (ABCC2) in human corneal epithelium and rabbit cornea and its role in ocular drug effluxT-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.Acute myeloid leukemia stem cells and CD33-targeted immunotherapyThe role of gemtuzumab ozogamicin in acute leukaemia therapy.Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins.Current therapeutic strategies for acute myeloid leukaemia.Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenograftsA phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicinCellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia.Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy.Investigational antibody-drug conjugates for hematological malignancies.Designing immunoconjugates for cancer therapy.Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.Importance of ABCC1 for cancer therapy and prognosis.Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells.Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity.MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia.NFATc1 as a therapeutic target in FLT3-ITD-positive AML.Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicinGemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo.High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients.Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia.Breast cancer resistance protein (BCRP/ABCG2) does not confer resistance to gemtuzumab ozogamicin and calicheamicin-gamma1 in acute myeloid leukemia cells.Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin.
P2860
Q24678297-103C9E6A-03F9-49C2-8E32-9E960D3482BAQ28484890-61047287-5C66-4CFE-B561-B29B10CDE0F1Q28543175-25C1862F-3E7F-4D7F-BD33-05C6A022ADAEQ33281867-9C19FB40-2869-4192-96B5-C0788FD758EFQ33319637-FC3B3A8A-3EDE-46A7-AEC3-F12F85DE8EB6Q33361455-47A3E054-7AB0-4E33-8CED-9CC9F623DC03Q33373033-C49A72E0-447A-46F7-B162-B4F9E6329D74Q33472987-C28A3AAE-5860-4A68-B78B-0F37C022B937Q33651005-B07FC9CD-C35B-4502-B027-3C1DCF9EB327Q33692521-01A037A1-5462-462E-BB4A-EBB1DE922A8BQ34421932-E4E265F5-8BAB-4696-B64B-A010DD6CAAF7Q35847659-72B0429C-E284-4968-BD6F-107999275385Q35980938-6593E8D5-5CDF-4572-83A0-CB1C3026C4FCQ36015676-20E0036A-F994-4579-B9B4-D45FC3A959DAQ36022539-D5D23AA5-BF7A-4E35-9523-539DF5E30E71Q36058588-1313B99A-9EE7-41EC-B023-A55A9FA5CDBCQ36367816-EF182D6A-6F18-44E1-A966-0708CA889435Q36525551-06E45154-97F8-45B6-B2F2-8D652F8D3B24Q36539598-D433B408-B9E2-469E-964B-1FE6DCA32081Q36591404-DB257079-9460-43B6-815C-ADD519D2EE77Q36682845-8A654582-5FF1-4F88-9896-28DEF4AE75A0Q36932014-11C7ED02-6A9D-4C39-9C0F-E55A6770D64DQ37512086-62645F5C-108F-4054-AE75-2430EB48BFF3Q37536546-699F0640-168D-448A-8634-BFC2AA6D74B9Q37818248-BE7E80F8-113F-439E-9CE0-E966FF811B1BQ37818256-A7208874-CBB9-4707-BDD5-C6A8A0AF4052Q38017203-643E575E-1D2B-47ED-9BE5-BD5B10A37081Q38109541-F2C3BD16-89F1-406B-B95A-C77519CFD9E3Q38199535-932F7CDC-4BE0-4B2B-ADE9-E0077B831221Q39506455-B0A33D1A-B444-4836-AAA4-B11AB566EA8EQ40184984-1D446EC5-3C7C-46C1-9A88-BDD2126F182DQ40451918-8A9B6129-2586-4034-97B9-F6A8B5CB3B04Q40937224-4D9E4E85-2176-473E-95DD-876FCFE579DBQ42695542-9E244FFC-B551-4BD4-9812-D37EF5EF342AQ45236184-6D7B1BB7-1F49-4DB2-982C-AAD28494D00FQ47929658-F9613A44-E72A-414E-9DC7-D420319ACA97Q53369470-A778401A-7EC5-44D4-879B-74A8A29366B4Q53884567-FE5C1E96-A15B-41E1-BA29-FDE0F2121AAFQ54329544-3990C956-6DDC-4035-8F85-E16DDBB42390
P2860
Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Multidrug resistance protein a ...... acute myeloid leukemia cells.
@en
Multidrug resistance protein a ...... acute myeloid leukemia cells.
@nl
type
label
Multidrug resistance protein a ...... acute myeloid leukemia cells.
@en
Multidrug resistance protein a ...... acute myeloid leukemia cells.
@nl
prefLabel
Multidrug resistance protein a ...... acute myeloid leukemia cells.
@en
Multidrug resistance protein a ...... acute myeloid leukemia cells.
@nl
P2093
P921
P1433
P1476
Multidrug resistance protein a ...... acute myeloid leukemia cells.
@en
P2093
Brian W Raden
David A Flowers
Irwin D Bernstein
Michael L Linenberger
Tom C Hong
P304
P356
10.1182/BLOOD-2003-02-0396
P407
P577
2003-04-10T00:00:00Z